ArteraAI Breast Cancer Assay

CE | Breast | Amplifier Integrator | H&E

Amplifier Marketplace Pathology

Description of use

The ArteraAI Breast Cancer Assay is an in vitro diagnostic medical device software device based on artificial intelligence (AI) that assesses physician-provided clinical variables and whole slide images (WSI) of Breast Resection specimens to provide risk estimates of Distant Metastasis for patients with HR+/ HER2-, N0 or N1, early stage invasive breast cancer breast cancer. The specimens must be prepared from hematoxylin & eosin (H&E) stained formalin-fixed paraffin-embedded (FFPE) tissue. Physician-provided clinical variables are age, tumor size, and nodal status.
It provides individual 5- and 10-year risks of distant metastasis, ArteraAI Risk score and risk group. ArteraAI Risk group has been shown to be predictive of chemotherapy benefit in patients aged >50 with N0 disease.

How is the application integrated?

• Application can be launched from Sectra's pathology image window: Yes
• Results will be shown in Sectra's pathology image window: Yes

Ask your Sectra representative which version of the Sectra PACS is compatible with the highlighted integration standards.

Contact us

Referring articles

The below are peer-reviewed articles that have been submitted by the AI vendor to serve as scientific validation of the application.

Other applications by this vendor

ArteraAI Breast
FDA | H&E
ArteraAI Breast provides 5- and 10-year risks of distant metastasis and ArteraAI risk score for HR+/HER2-, N0 or N1, early stage invasive breast cancer patients, to assist physicians with prognostic risk-based decisions with other clinical factors.
ArteraAI Prostate
FDA | H&E
ArteraAI Prostate is a software only device intended to analyze scanned histopathology whole slide images from treatment-naïve prostate core needle biopsies. It provides 10-year risks of distant metastasis and prostate cancer specific mortality.
ArteraAI Prostate Biopsy Assay
CE | H&E
ArteraAI Prostate Biopsy Assay is an IVD software based on AI that assesses clinical variables and H&E stained WSIs of prostate biopsies to provide risk estimates of disease prognosis and prediction of risk appropriate treatment benefit

Let’s talk

Are you interested in learning more? Please do not hesitate to get in touch with us at Sectra.

Contact us

The application content is provided by the respective AI vendors.